Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,116 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,685 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,163)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02414100 | Patient Derived Cancer Cell Lines in Identifying Molecular Changes in Patients With Previously Untreated Pancreatic Cancer Receiving Gemcitabine Hydrochloride-Based Chemotherapy | withdrawn | — | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02548468 | Reduced Intensity Conditioning Before Partially Matched Donor Stem Cell Transplant in Treating Patients With Advanced Cutaneous T Cell Lymphoma | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University |
| 0 |
| May 2, 2025 |
| clinicaltrials |
| NCT02671552 | Contrast-Enhanced Ultrasound in Predicting Treatment Response in Patients With Kidney Cancer Undergoing Cryosurgery | withdrawn | Early Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT06644079 | Window of Opportunity Study of Topical Tranexamic Acid for Cutaneous Squamous Cell Carcinoma | withdrawn | Phase 2 | 0 | University of FloridaOTHER | 0 | May 2, 2025 | clinicaltrials |
| NCT02591433 | JeffQuit Group Therapy Program for Smoking Cessation in Patients With a History of Cancer | withdrawn | N/A | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT03560908 | Dasatinib Combined With Chemotherapy in Relapsed t(8;21) Acute Myeloid Leukemia With KIT D816 Mutation | withdrawn | Phase 1 | 0 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT06834386 | Suvorexant for Insomnia to Prevent Delirium in Hospitalized Cancer Patients | withdrawn | Phase 4 | 0 | Mayo ClinicOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT03288818 | Low Dose Total Skin Electron Beam Radiation Therapy and Mechlorethamine Hydrochloride Gel in Treating Patients With Mycosis Fungoides | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03374852 | CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer | withdrawn | Phase 2 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT03477864 | Stereotactic Body Radiation Therapy With REGN2810 and/or Ipilimumab Before Surgery in Treating Participants With Progressive Advanced or Oligometastatic Prostate Cancer | withdrawn | Phase 1 | 0 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 0 | Apr 29, 2025 | clinicaltrials |
| NCT04418219 | Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT05595135 | Mobile Intervention to Improve Adherence of Oral Anti-cancer Medications Among Acute Myeloid Leukemia Patients, the txt4AML Study | withdrawn | N/A | 0 | Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT02939807 | A Phase II Study of ABC294640 as Monotherapy in Patients With Advanced Hepatocellular Carcinoma | withdrawn | Phase 2 | 0 | Medical University of South CarolinaOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT04595981 | Chemo-embolization for Head and Neck Cancer | withdrawn | Phase 2 | 0 | University of Alabama at BirminghamOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06795178 | Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg in Patients With Advanced Prostate Cancer(KATANA E3M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06795191 | Efficacy, Safety, and Pharmacokinetics of FP-014, 22.5 mg in Patients With Advanced Prostate Cancer(KATANA E6M) | withdrawn | Phase 3 | 0 | Foresee Pharmaceuticals Co., Ltd.INDUSTRY | 0 | Apr 27, 2025 | clinicaltrials |
| NCT06522360 | Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Apr 24, 2025 | clinicaltrials |
| NCT03581500 | Hyperpolarized Carbon C 13 Pyruvate Magnetic Resonance Spectroscopic Imaging in Predicting Treatment Response in Patients With Prostate Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT06938711 | A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Context Therapeutics Inc.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04485026 | Local Consolidative Radiotherapy for Oligoprogressive in Non-small Cell Lung Carcinoma | withdrawn | Phase 2 | 0 | Wake Forest University Health SciencesOTHER | 0 | Apr 17, 2025 | clinicaltrials |
| NCT05358691 | A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants | withdrawn | Phase 1 | 0 | Rutgers, The State University of New JerseyOTHER | 1 | Apr 16, 2025 | clinicaltrials |
| NCT05815316 | 18F-PSMA PET/MRI for the Diagnosis of Clinically Significant Prostate Cancer | withdrawn | Phase 2 | 0 | IRCCS San RaffaeleOTHER | 0 | Apr 13, 2025 | clinicaltrials |
| NCT05648188 | A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells(LUNGadenosine) | withdrawn | — | 0 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Apr 10, 2025 | clinicaltrials |
| NCT05900908 | Post-operative Adjuvant Therapy w/wo GammaTile + Systemic Therapy(PATHWAyS) | withdrawn | Phase 4 | 0 | GT Medical Technologies, Inc.INDUSTRY | 0 | Apr 10, 2025 | clinicaltrials |
| NCT05940844 | Study of OB-002 in Patients With Refractory Metastatic Cancer | withdrawn | Phase 1 | 0 | Orion Biotechnology Polska Sp. z o.o.INDUSTRY | 0 | Apr 9, 2025 | clinicaltrials |
| NCT06895941 | Predictive Value of PET/CT for Efficacy of Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer | withdrawn | — | 0 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Apr 8, 2025 | clinicaltrials |
| NCT05126342 | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After Treatment With PARPi | withdrawn | Phase 2 | 0 | AGO Research GmbHINDUSTRY | 0 | Apr 6, 2025 | clinicaltrials |
| NCT05608369 | Vorinostat in Combination With Chemoradiation in Locally Advanced HPV Negative HNSCC(HPV) | withdrawn | Phase 2 | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06422312 | A Study Comparing a Disposable Flexible Cystoscope With Reusable Scopes in Adult Patients. | withdrawn | N/A | 0 | Guangzhou Red Pine Medical Instrument Co., Ltd.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
| NCT06094842 | Autologous T Cells Lentivirally Transduced to Express L1CAM-Specific Chimeric Antigen Receptors in Treating Patients With Locally Advanced and Unresectable or Metastatic Small Cell Neuroendocrine Prostate Cancer | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol VHIO21001 - LiDer(LiDer) | withdrawn | Phase 1 / Phase 2 | 0 | Vall d'Hebron Institute of OncologyOTHER | 0 | Apr 1, 2025 | clinicaltrials |
| NCT01345084 | Study Comparing Radiation Therapy and Chemotherapy With or Without Nimotuzumab(NICAP) | withdrawn | Phase 3 | 0 | Eurofarma Laboratorios S.A.INDUSTRY | 1 | Mar 28, 2025 | clinicaltrials |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | withdrawn | — | 0 | WellSpan HealthOTHER | 1 | Mar 28, 2025 | clinicaltrials |
| NCT01372696 | Endoscopic Characteristics of Colonic Tumours(C-LST) | withdrawn | N/A | 0 | Professor Michael BourkeOTHER | 1 | Mar 27, 2025 | clinicaltrials |
| NCT03636607 | Diagnostic Significance of Single Center, Open and Prospective Evaluation of <Sup>18<Sup>F-FDG PET/CT Dynamic Imaging and Genomic Sequencing in Detecting Metastatic Lesions of Primary Hepatocellular Carcinoma | withdrawn | N/A | 0 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 1 | Mar 24, 2025 | clinicaltrials |
| NCT06351306 | DEC-C and Thioguanine for R/R AML | withdrawn | Phase 2 | 0 | Columbia UniversityOTHER | 0 | Mar 24, 2025 | clinicaltrials |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer | withdrawn | — | 0 | PfizerINDUSTRY | 0 | Mar 19, 2025 | clinicaltrials |
| NCT04976660 | TT-4 As a Single Agent in Subjects with Advanced Selected Solid Tumors | withdrawn | Phase 1 / Phase 2 | 0 | Tarus Therapeutics, Inc.INDUSTRY | 0 | Mar 18, 2025 | clinicaltrials |
| NCT05452408 | Antitumor-B KAC PK Study | withdrawn | Phase 1 | 0 | Medical College of WisconsinOTHER | 1 | Mar 18, 2025 | clinicaltrials |
| NCT06144827 | A Pilot Study For Patients Receiving Radiation Therapy for Liver Cancer(HepQuant) | withdrawn | N/A | 0 | Montefiore Medical CenterOTHER | 0 | Mar 18, 2025 | clinicaltrials |
| NCT04958967 | Phase Ib Study of FURMONERTINIB in Patients with NSCLC Having Exon 20 Insertion Mutation | withdrawn | Phase 1 | 0 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 14, 2025 | clinicaltrials |
| NCT05584540 | UNTIRE: Cancer-related Fatigue With Digital Treatment | withdrawn | N/A | 0 | Dana-Farber Cancer InstituteOTHER | 1 | Mar 12, 2025 | clinicaltrials |
| NCT06113289 | A Phase 1B/2A Trial of Combination of ASTX727 With ASTX029 in Acute Myeloid Leukemia | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 12, 2025 | clinicaltrials |
| NCT05743270 | Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN | withdrawn | Phase 2 | 0 | Replimune, Inc.INDUSTRY | 8 | Mar 11, 2025 | clinicaltrials |
| NCT04696263 | Single-Port Versus Multi-Port Robotic Radical Prostatectomy | withdrawn | N/A | 0 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 10, 2025 | clinicaltrials |
| NCT05470309 | Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women in Cleveland | withdrawn | — | 0 | MetroHealth Medical CenterOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06094621 | Effect of Pre-operative Virtual Visits on Patients With Head and Neck Cancer Undergoing Surgery | withdrawn | — | 0 | University of Michigan Rogel Cancer CenterOTHER | 0 | Mar 7, 2025 | clinicaltrials |
| NCT05486481 | Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) | withdrawn | Phase 1 / Phase 2 | 0 | Alfred Chung, MDOTHER | 0 | Mar 6, 2025 | clinicaltrials |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | withdrawn | Phase 1 / Phase 2 | 0 | Centre Hospitalier Universitaire VaudoisOTHER | 0 | Mar 5, 2025 | clinicaltrials |
Data updated 23 days agoSource updated May 2, 2025source: clinicaltrials